Home » U.S. FDA Bests EMA in Cancer Drug Approval Times, Study Finds
U.S. FDA Bests EMA in Cancer Drug Approval Times, Study Finds
September 10, 2012
The U.S. Food and Drug Administration (FDA) continues to approve cancer drugs more quickly than the European Medicines Agency (EMA), clearing them in about half the time regardless of the drug’s designation, according to a recent study.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor